The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
NCRI 2016 | APOBEC-3B, a candidate biomarker for response to therapy
Reuben Harris, PhD of University of Minnesota, Minneapolis, MN talks about APOBEC-3B as a candidate biomarker for response to therapy. Tumors expressing higher levels of APOBEC-3B and APOBEC-3H are more likely to have a higher overall mutation rate and evolvability. Dr Harris points out that targeted therapies could become undermined by resistance mutations, especially in a tumor that is mutating at a high rate. Recorded at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK.
